Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 248

    1.

    Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

    Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group.

    Diabetes Care. 2006 Dec;29(12):2632-7.PMID: 17130196 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

    Diabetes Care. 2006 Dec;29(12):2638-43.PMID: 17130197 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

    Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group.

    Diabetologia. 2006 Nov;49(11):2564-71. Epub 2006 Sep 26.PMID: 17001471 [PubMed - indexed for MEDLINE]Related articles

    5.

    Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

    Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group.

    Diabetes Care. 2007 Aug;30(8):1979-87. Epub 2007 May 7. Erratum in: Diabetes Care. 2008 Aug;31(8):1713. PMID: 17485570 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

    Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators.

    Curr Med Res Opin. 2007 Jun;23(6):1329-39. Epub 2007 Apr 30.PMID: 17559733 [PubMed - indexed for MEDLINE]Related articles

    7.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

    Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.PMID: 17593236 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

    Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP.

    Diabetes Obes Metab. 2007 Mar;9(2):186-93.PMID: 17300594 [PubMed - indexed for MEDLINE]Related articles

    9.

    Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.

    Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP.

    Diabetes Res Clin Pract. 2008 Feb;79(2):291-8. Epub 2007 Oct 22.PMID: 17933414 [PubMed - indexed for MEDLINE]Related articles

    10.
    11.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

    Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

    J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.PMID: 16912128 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.

    Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M.

    Curr Med Res Opin. 2008 Feb;24(2):537-50.PMID: 18194595 [PubMed - indexed for MEDLINE]Related articles

    14.

    Sitagliptin.

    Lyseng-Williamson KA.

    Drugs. 2007;67(4):587-97. Review.PMID: 17352516 [PubMed - indexed for MEDLINE]Related articles

    15.

    Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

    Scott R, Wu M, Sanchez M, Stein P.

    Int J Clin Pract. 2007 Jan;61(1):171-80. Epub 2006 Dec 5.PMID: 17156104 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus.

    Nonaka K, Tsubouchi H, Okuyama K, Fukao Y, Johnson-Levonas AO, Amatruda JM.

    Horm Metab Res. 2009 Mar;41(3):232-7. Epub 2009 Feb 27.PMID: 19253204 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.

    Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.

    Diabetes Obes Metab. 2008 Dec;10(12):1212-20. Epub 2008 May 12.PMID: 18476982 [PubMed - indexed for MEDLINE]Related articles

    18.

    Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.

    Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD.

    Diabetes Res Clin Pract. 2009 Jan;83(1):106-16. Epub 2008 Dec 20.PMID: 19097665 [PubMed - indexed for MEDLINE]Related articles

    19.

    Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.

    Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group.

    Diabetes Obes Metab. 2008 Sep;10(10):959-69. Epub 2008 Jan 14.PMID: 18201203 [PubMed - indexed for MEDLINE]Related articles

    20.

    Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.

    Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D.

    Diabetes Obes Metab. 2008 Jul;10(7):545-55. Epub 2008 Jun 1.PMID: 18518892 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data